HOME ·

02617.HK

TRANSTHERA-B (02617.HK) plans to issue in total 3.84 million shares by placement, with estimated net proceeds of HKD 152.13 million
Tags：
TRANSTHERA-B02617.HKshare placement
2026-05-19
TRANSTHERA-B (02617.HK): Clinical Data of Core Product Tiengrtinib Published in Nature Communications
Tags：
TRANSTHERA-B02617.HKclinical development
2026-05-17
TransThera Sciences-B (02617.HK): Successfully Completes H-Share Placement, Raising Approximately HK$190 Million to Fund Core Product R&D
Tags：
TRANSTHERA-B02617.HKH-share placement
2026-01-20